Drugs / 14 Nitrogen (N) Sodium Nitrite
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT02517697 | Oct 2020 → Apr 2021 | hypertensive disorder, metabolic syndrome X | Gladwin, Mark, MD | Withdrawn | No outcome recorded Stop: Enrollment |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 14 Nitrogen (N) Sodium Nitrite | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02517697 ↗ |
| Route | Oral | “oral formulation of sodium nitrite 40 mg three times daily for 12 weeks” NCT02517697 ↗ |